What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database

References

• Nielsen J, Young C, Ifteni P, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30(2):149–161.
   PubMed Web of Science ®Google Scholar
• Base de données publique du médicament. Résumé des caractéristiques du produit - CLOZAPINE BIOGARAN 100 mg, comprimé sécable - Base de données publique des médicaments 2020. http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=61491877&typedoc=R ( accessed December 20, 2019).
   Google Scholar
• Rang HP, Dale MM, Ritter JM. Rang and Dale’s pharmacology. Edinburgh: Elsevier; 2020.
   Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–796.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge: Cambridge University Press; 2013.
   Google Scholar
• Huguet G, Lillo-Le Louet A, Darnige L, et al. [Clozapine rechallenge in resistant schizophrenia disorder affecting “super sensitive” patients, after neutropenia under clozapine: a case report]. Encephale. 2013;39(Suppl 1):S42–48.
   PubMed Web of Science ®Google Scholar
• Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv. 1996;47:52–56.
   PubMed Web of Science ®Google Scholar
• Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl 3):3–7.
   PubMed Web of Science ®Google Scholar
• Ismail D, Tounsi K, Zolezzi M, et al. A qualitative exploration of clozapine prescribing and monitoring practices in the Arabian Gulf countries. Asian J Psychiatr. 2019;39:93–97.
   PubMed Web of Science ®Google Scholar
• García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36(4):355–371.
   PubMed Web of Science ®Google Scholar
• Ingimarsson O, MacCabe JH, Haraldsson M, et al. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC Psychiatry. 2016;16(1):441.
   PubMed Web of Science ®Google Scholar
• Gérardin M, Rousselet M, Caillet P, et al. French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol. BMJ Open. 2019;9(6):e027443.
   PubMed Web of Science ®Google Scholar
• Scailteux L-M, Droitcourt C, Balusson F, et al. French administrative health care database (SNDS): the value of its enrichment. Therapies. 2019;74(2):215–223.
   PubMed Web of Science ®Google Scholar
• Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962.
   PubMed Web of Science ®Google Scholar
• Bulteau S, Le Pierres M, Artarit P, et al. Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database. Expert Opin Drug Saf. 2020;1–9. DOI:https://doi.org/10.1080/14740338.2021.1851678
   Google Scholar
• Mohamed S, Rosenheck R, McEvoy J, et al. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35(2):336–346.
   PubMed Web of Science ®Google Scholar
• Glick HA, Li P, Harvey PD. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial. Schizophr Res. 2015;166(1–3):110–114.
   PubMed Web of Science ®Google Scholar
• Kiviniemi M, Suvisaari J, Isohanni M, et al. The characteristics and outcomes of hospitalised and outpatient-treated first-onset schizophrenia patients: a 5-year register linkage study. Int J Clin Pract. 2013;67(11):1105–1112.
   PubMed Web of Science ®Google Scholar
• Legge SE, Hamshere M, Hayes RD, et al. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res. 2016;174(1–3):113–119.
   PubMed Web of Science ®Google Scholar
• Ingimarsson O, MacCabe JH, Haraldsson M, et al. Clozapine treatment and discontinuation in Iceland: a national longitudinal study using electronic patient records. Nord J Psychiatry. 2016;70(6):450–455.
   PubMed Web of Science ®Google Scholar
• Cohen D. Prescribers fear as a major side-effect of clozapine. Acta Psychiatr Scand. 2014;130(2):154–155.
   PubMed Web of Science ®Google Scholar
• Bogers JPAM, Schulte PFJ, Van Dijk D, et al. Clozapine Underutilization in the Treatment of Schizophrenia: how Can Clozapine Prescription Rates Be Improved? J Clin Psychopharmacol. 2016;36(2):109–111.
   PubMed Web of Science ®Google Scholar
• Mouaffak F, Foulon S, Smail F, et al. Clozapine: les dernières recommandations de la FDA et nous …. L’Encéphale. 2016;42(6):600–601.
   PubMed Web of Science ®Google Scholar
• Verdoux H, Quiles C, Bachmann CJ, et al. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res. 2018;201:10–19.
   PubMed Web of Science ®Google Scholar
• Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother. 2008;42(6):852–860.
   PubMed Web of Science ®Google Scholar
• Bogers JPAM, Bui H, Herruer M, et al. Capillary compared to venous blood sampling in clozapine treatment: patients׳ and healthcare practitioners׳ experiences with a point-of-care device. Eur Neuropsychopharmacol. 2015;25(3):319–324.
   PubMed Web of Science ®Google Scholar
• Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116(5):317–333.
   PubMed Web of Science ®Google Scholar
• McLean G, Hindle JV, Guthrie B, et al. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17(1):126.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Gerhard T, Crystal S, et al. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. AJP. 2015;173(2):166–173.
   Web of Science ®Google Scholar